Drug
Milvexian clinical trials
Also written BMS-986177 and JNJ-70033093.
- studies test it
- 25
- open now
- 0
- in phase 3
- 3
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
25 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 4 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 20
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 0
Bristol-Myers Squibb (14) · Janssen Research & Development, LLC (9) · Janssen Pharmaceutica N.V., Belgium (2)
Often tested with
Tested in the same studies.
Atorvastatin (1) · Digoxin (1) · Midazolam (1) · Ethinyl Estradiol (1) · Drospirenone (1) · Clopidogrel (1) · Aspirin (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses milvexian is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05757869Written as Milvexian
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05702034Written as Milvexian
- A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeCompletedPhase 3Janssen Research & Development, LLCNCT05754957Written as Milvexian
- A Study of JNJ-70033093 (Milvexian) in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04844424Written as Milvexian
- A Study of JNJ-70033093 (BMS-986177) in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04223349Written as JNJ-70033093
- A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy ParticipantsCompletedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT04388501Written as Milvexian
- A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04569695Written as JNJ-70033093
- A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement SurgeryCompletedPhase 2Janssen Research & Development, LLCNCT03891524Written as JNJ-70033093 25 mg
- A Study of JNJ-70033093 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04448964Written as JNJ-70033093
- A Study of JNJ-70033093 and Digoxin in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04206488Written as JNJ-70033093
- A Study of Milvexian in Healthy Adult FemalesCompletedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT05706753Written as Milvexian
- A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04965389Written as BMS-986177 Oral Solution
- A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelCompletedPhase 2Bristol-Myers SquibbNCT03766581Written as BMS-986177
- Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT03196206Written as BMS-986177
- A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT03698513Written as BMS-986177
- A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With HemodialysisCompletedPhase 1/2Bristol-Myers SquibbNCT03000673Written as BMS-986177
- Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03939702Written as BMS-986177
- Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT02982707Written as BMS-986177
- To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03224260Written as BMS-986177
- Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03362437Written as BMS-986177
See all 25 studies that test milvexian →
Given in every arm · 1 — milvexian is usual care beside what is tested
Codes
What other systems call milvexian · ClinicalTrials.gg INT001772
- MeSH (NLM) C000720754milvexianOne source NLM
- UNII (FDA) 0W79NDQ608MILVEXIANConfirmed FDA, NLM, Wikidata
- Wikidata Q109655049milvexianConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175138MilvexianOne source FDA
- DrugBank DB16233One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720754 | milvexian | One source NLM |
| UNII (FDA) | 0W79NDQ608 | MILVEXIAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q109655049 | milvexian | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175138 | Milvexian | One source FDA |
| DrugBank | DB16233 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.